Massimo Massaia
Associate Professor of Hematology
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
This real-world prospective observational study across 21 Italian centers ( CART-SIE ) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, P = 0.0017) and neurotoxicity (9.9% vs. 32.2%, P P = 0.0009). Even among patients who failed bridging therapy, axi-cel PFS was superior to tisa-cel (37.5% vs. 22.7%, P = 0.0059). Differences in overall survival and high-grade immune toxicities were not significant. The CAR-HEMATOTOX score not only predicted hematologic toxicity but also 1-year survival outcomes (51.5% in CAR-HEMATOTOX high vs. 77.2% in CAR-HEMATOTOX low, P Significance: The findings of this study on 485 patients with relapsed/refractory large B-cell lymphoma treated with commercial axi-cel and tisa-cel indicate axi-cel’s superior PFS after propensity score weighting. The predictive utility of CAR-HEMATOTOX in assessing not only toxicity but also outcomes across both CAR T-cell products may guide future risk-stratified management strategies.
Year:
2024
This real-world prospective observational study across 21 Italian centers ( CART-SIE ) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, P = 0.0017) and neurotoxicity (9.9% vs. 32.2%, P P = 0.0009). Even among patients who failed bridging therapy, axi-cel PFS was superior to tisa-cel (37.5% vs. 22.7%, P = 0.0059). Differences in overall survival and high-grade immune toxicities were not significant. The CAR-HEMATOTOX score not only predicted hematologic toxicity but also 1-year survival outcomes (51.5% in CAR-HEMATOTOX high vs. 77.2% in CAR-HEMATOTOX low, P Significance: The findings of this study on 485 patients with relapsed/refractory large B-cell lymphoma treated with commercial axi-cel and tisa-cel indicate axi-cel’s superior PFS after propensity score weighting. The predictive utility of CAR-HEMATOTOX in assessing not only toxicity but also outcomes across both CAR T-cell products may guide future risk-stratified management strategies.
Year:
2024
Collaborators (13)
Armando Santoro
Professore
Humanitas University
Federica Cavallo
University of Turin
Paolo Corradini
Full Professor of Hematology
University of Milan
PIER LUIGI ZINZANI
University of Bologna
Mauro Krampera
Docenti di ruolo di Ia fascia
University of Verona
Luca Arcaini
Director of Division of Hematology
Fondazione IRCCS Policlinico San Matteo
Domenico Russo
University of Brescia
Federica Sora'
professor
Università Cattolica del Sacro Cuore
Marco LADETTO
Associate Professor
Università degli Studi del Piemonte Orientale
Patrizia Chiusolo
Università Cattolica del Sacro Cuore
Massimo Martino
Director Stem Cell Transplant Program
Azienda ospedaliera "Bianchi-Melacrino-Morelli"
Silva Ljevar
Fondazione IRCCS Istituto Nazionale dei Tumori
ANNALISA CHIAPPELLA
Fondazione IRCCS Istituto Nazionale dei Tumori
Make your next move.
Prepare your application
Review drafts before you send them.